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ABSTRACT 
 
Background 
Sub-Saharan Africa, the epicenter of the global population of people living with HIV (PLHIV), 
is estimated to have more than 25 million PLHIV.  In the era before the widespread availability 
of antiretroviral therapy (ART), anaemia (low serum haemoglobin) was a common clinical 
finding that was seen as a potential risk factor for HIV-associated neurocognitive impairment. 
The association between haemoglobin levels and neurocognitive function has not been assessed 
in a Sub-Saharan study population in the era of ART.    
Methods 
A cross-sectional secondary data analysis was performed to assess the association between serum 
haemoglobin level and neurocognitive function in 129 participants who had both neurocognitive 
test (global deficit score) and full blood count results performed as part of a randomised placebo 
controlled trial that evaluated the efficacy of lithium carbonate for the treatment of HIV 
associated neurocognitive disorders. 
Results 
The majority of our participants were female (87%) with a mean age of 37 ±7.78 years.  
Participants were all established on ART with a median CD4 count of 495 cells/µL (IQR=315-
629).  The median haemoglobin level was 12.2 (IQR=11.6-13.00) and anaemia was present in 
8.5%.  Serum haemoglobin level was not associated with global deficit scores (GDS) and fewer 
years of education was the only independent risk association for GDS-defined neurocognitive 
impairment.   
Conclusion 
We found that in South Africans, who are established on ART, anaemia is less common than in 
the pre-ART era and importantly, that low-normal serum Hb levels do not present a risk for 
GDS-defined neurocognitive impairment. These findings are relevant as they show that 
aggressive management of low-normal Hb levels is not necessary provided individuals are 
otherwise clinically well and virally suppressed.     
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CHAPTER 1 
1     Background 
1.1     Human immune deficiency virus (HIV) associated neurocognitive disorders - an 
introduction 
The global estimate of people living with HIV (PLHIV) is 36.9 million (UNAIDS 2015 
Factsheet).  Sub-Saharan Africa continues to carry the largest burden of this disease with 
an estimated 25.8 million PLHIV.  In the last two decades major strides have been made 
with regards to improved access and the early initiation of antiretroviral therapy (ART).  
This has had an impact on the epidemiology and presentation of clinical syndromes 
associated with HIV.  Previously, typical complications of HIV related to severe immune 
compromise.  However, in the modern era of ART, HIV has increasingly been associated 
with conditions related to chronic low-grade immune dysregulation, accelerated cellular 
aging and the negative effects of long term ART use. (1)  
This change in the clinical picture of HIV is particularly evident with regards to the 
neurocognitive disorders associated with HIV.  In the 1980’s and early 1990’s advanced 
HIV infection was frequently complicated by a progressive subcortical dementia with 
psychomotor slowing and severe cognitive impairment, a condition then called HIV-
dementia (HAD). (2)  More recently, since the advent of ART, the incidence of HIV-
dementia  has been reduced. (3)  However, as ART use became more widespread, it was 
evident that milder forms of neurocognitive impairment were common amongst PLHIV.  
It was suggested that an estimated 50% of PLHIV who are clinically stable and receiving 
ART could be expected to have neurocognitive impairment on objective 
neuropsychological testing. (4)   The emergence of this spectrum of neurocognitive 
impairment saw an expansion of the nosology used to describe HIV associated 
neurocognitive impairment. (5)   
HIV associated neurocognitive disorders (HAND) now serves as an umbrella term which 
can be further defined on the basis of both the degree of functional impairment and the 
associated objective neuropsychological test findings.  As the term suggests, the 
individual with asymptomatic neurocognitive impairment (ANI) does not subjectively 
experience any impairment in everyday functioning but neuropsychological testing 
demonstrates a performance of at least 1.0 standard deviation (SD) below the mean for 
age-education-appropriate norms.  In mild neurocognitive disorder (MND) the individual 
has some degree of interference with day-to-day cognitive functioning and 
neuropsychological testing demonstrates a performance of at least 1.0 SD below the 
mean for age-education-appropriate norms.  HIV- associated dementia (HAD) represents 
the most severe form of impairment and the patient typically has marked interference 
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with daily functioning with neuropsychological testing demonstrating a performance of 
greater than 2.0 SD below demographically corrected means. (5) 
Epidemiological data suggests that amongst PLHIV who are receiving ART 
approximately: 30% have ANI, 20% have MND and 2% - 8% have HAD. (6)  The 
overall figure of HAND is expected to rise even further as the global HIV positive 
population ages. (6)   
 
HAND is associated with significant morbidity and has been shown to have a negative 
impact on everyday function, employability as well as ART adherence. (7, 8, 9)   
There is no definitive adjuvant treatment for the management of HAND in PLHIV who 
are clinically stable on ART. (6, 10) 
 
 
1.2 The pathophysiology of HAND 
HIV enters the brain in the early phase of systemic infection. (11)  The most widely 
accepted hypothesis of neuro-invasion suggests that HIV crosses the blood brain barrier 
through infected macrophages and microglia. (6)  Since neurons do not express the 
glycoproteins that render cells susceptible to HIV infection, HIV cannot directly infect 
neurons.  The neurodegenerative mechanisms, which underlie HAND, must therefore 
occur via an alternative mechanism.  Two non-mutually exclusive models of neuronal 
injury have been suggested: the direct injury hypothesis and the bystander effect 
hypotheses.   
The direct injury hypothesis proposes that viral proteins such as glycoprotein 120 (gp120) 
are able to interact with chemokine and N-Methyl-D-Aspartate (NMDA) receptors. This 
activates intracellular secondary messenger systems which may initiate apoptotic 
pathways and give rise to neuronal injury.  Gp120 can also stimulate non-neuronal cells 
to produce tumor-necrosis factor (TNF).  TNF activates further cellular cascades that 
ultimately lead to neuronal cell death. (6)    
Two additional viral proteins, Tat and Vpr, have also been suggested as potential 
contributors to neuronal injury.  In a similar fashion to TNF, Tat and Vpr can disrupt 
intracellular processes and thereby induce intracellular injury. (6)       
The bystander effect hypothesis suggests that HIV infection in the central nervous system 
activates inflammatory pathways that ultimately lead to neuronal injury.  HIV activates 
microglia and brain macrophages.  These activated immune cells then initiate an 
inflammatory cascade through the release of TNF and other pro-inflammatory cytokines.  
This inflammatory response can in turn activate uninfected cells and in doing so, lead to 
the amplification of HIV-induced neurotoxicity.  In addition, it is thought that this 
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inflammatory response can impair the function of astrocytes that usually serve as 
neuronal support cells. (6)   
The widest held aetiological understanding of the HAND disorders views the degrees of 
clinical severity as occurring along a spectrum that correlates with the underlying degree 
of neurodegenerative insult. (6)  It remains uncertain why PLHIV are more likely to 
experience HAND but current evidence suggests a complex, multifactorial risk profile 
which includes both viral and host-related risk factors.    
1.3 Risk factors associated with HAND 
Viral related factors  
1.3.1 Nadir CD4 
One of the most consistent risk factors associated with HAND is the severity of immune 
suppression as measured by the lowest (nadir) cluster of differentiation 4 T lymphocyte 
(CD4) count during HIV infection. (12, 13)  A period of severe immunosuppression prior 
to ART initiation appears to present an enduring risk for neurocognitive impairment even 
when ART has led to immune reconstitution. (13)     
It has been argued that severe immunosuppression invariably leaves the affected 
individual with neuronal injury. (14) Even though this initial neuronal damage may not 
be sufficient to induce functional impairment, it increases the individual’s susceptibility 
for developing symptomatic neurocognitive impairments. (14)  
It should be noted that current ART guidelines advocate for the early initiation of ART.  
As such, severe immunosuppression has become less common amongst PLHIV.  Due to 
this change, the strength of association between nadir CD4 and HAND has been reduced, 
highlighting the importance of additional HAND risk factors in the ART era. (6)   
Host related factors 
1.3.1 Genetic factors  
Apolipoprotein E is a protein that is involved in lipid metabolism in the brain.  
Individuals who are homozygous for the E4 allele of apolipoprotein E (Apo E4) have an 
increased risk of developing Alzheimer’s disease. (15) Apo E4 status has also shown 
some association with HAND in selected HIV-infected cohorts, particularly amongst 
older PLHIV. (16) This association has not been clearly replicated amongst younger 
PLHIV. (17, 18) 
The first genome wide association study for HAND conducted in a North American, 
HIV-infected, male population did not find any association between genetic susceptibility 
loci and HAND. (19)  Therefore, although it is possible that genetic predisposition may 
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play a role in the etiology of HAND, current evidence has not identified clear genetic risk 
factors. (18)  
 
1.3.2 Older age 
In HIV-infected populations, older age has been associated with an increased risk of 
HAND. (20-22)  Furthermore, as access to ART improves, HIV-infected populations 
grow older and therefore, the incidence of HAND increases in these populations. (4)  
 
It is well known that older age is a risk factor for age-related neurodegenerative 
conditions such as Alzheimer’s disease and vascular dementia.  Some researchers have 
suggested that the risk association and mechanism underlying cognitive impairment and 
age is similar in HIV-infected and HIV-uninfected populations. (23) Contrastingly, others 
have argued that HIV infection and/or ART accelerates the physiological aging process 
and as a result, neurodegenerative conditions may present earlier in PLHIV. (24) 
 
An additional factor that may be contributing to the cognitive decline noted in older 
individuals living with HIV is the increased frequency of comorbid vascular and 
metabolic conditions that have a well-established association with older age.   
 
1.3.4 Metabolic abnormalities and vascular disease 
The metabolic syndrome is a cluster of metabolic abnormalities that include 
hyperglycemia attributable to insulin resistance, hypertension, obesity, and dyslipidemias 
(elevated triglycerides and low-density lipoprotein cholesterol and decreased high-density 
lipoprotein cholesterol).  These metabolic abnormalities are common complications in 
individuals receiving ART. (25, 26) Metabolic abnormalities have been associated with 
neurocognitive impairment in HIV-uninfected populations. (27) For PLHIV, diabetes 
mellitus and increased central obesity appear to be of particular importance with regards 
to HAND risk. (28)  
 
1.3.5 Anaemia as potential risk factor for HAND 
Anaemia is the most common hematological abnormality in PLHIV with previously 
reported prevalence rates as high as 90% in the pre-ART era. (29)  The literature on 
anaemia reflects that different haemoglobin (Hb) levels are used as cutoff value to define 
anaemia.  Although anaemia can be defined as serum Hb value below the accepted 
population norms (<11.5g/dL in females and <13g/dL in males), most international and 
South African studies have used a more robust clinically significant cutoff value of 
<10g/dL, regardless of sex.   
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As with HAND, the introduction of ART markedly reduced the incidence and prevalence 
of anaemia in PLHIV.  In one of the first studies that assessed anaemia in a population 
receiving ART, the prevalence of anaemia was 11%. (30)  Others have since reported 
prevalence rates of 5.4% and 7.2% amongst North American women living with HIV. 
(19, 31)   
Prevalence rates for anaemia amongst South Africans receiving ART are limited.  In a 
South African study that screened more than 10000 individuals prior to ART initiation, 
the overall prevalence of anaemia (Hb <10g/dL) was 25.8%. (32)  This same study group 
later reported that in more than 80% of cases, pre-ART, anemia improved on ART. (33) 
Together these results suggest that in South Africa, the prevalence of anaemia amongst 
PLHIV, who are on established ART, is in the region of 5% - 10%.   
The pathophysiology of anaemia in PLHIV is thought to be multifactorial.  The most 
common form of anaemia in HIV is a normochromic normocytic anaemia with a low 
reticulocyte count, normal iron stores and impaired erythropoietin response.  This pattern 
of anaemia is typical of anaemia of inflammation.  It has been proposed that this form of 
anaemia is similar to that seen in anaemia of the elderly. (34)  It is suggested that it is 
accelerated senescence and immune dysregulation associated with HIV that are the major 
pathophysiological mechanisms underlying the majority of HIV associated anaemia. (35)    
Actively replicating HIV appears to suppress the body’s normal physiologic response to 
anaemia. (36)  In addition auto antibodies against erythropoietin has been demonstrated 
in HIV. (37)   
Nutritional deficiencies, also more common in PLHIV, often result in anaemia.  Namely, 
iron deficiency, associated with microcytic anaemia, and vitamin B12/folate deficiency is 
typically associated with macrocytic anaemia.  Opportunistic infections and malignancies 
associated with HIV can also cause anaemia. (35)  Lastly drugs used in HIV can in 
themselves result in anaemia including antiretroviral drugs, prophylactics for 
opportunistic infections and the drugs used in the treatment of opportunistic infections. 
(35) 
To explore the literature on a possible association between anaemia and HAND, a 
PubMed search was conducted using the following search terms: HIV, human 
immunodeficiency virus, acquired immune deficiency syndrome, AIDS (AND) 
neurocognitive impairment, neurocognitive disorder, HAND (AND) haemoglobin, 
hemoglobin, anemia and anaemia.  This search yielded twenty-five results.  Screening of 
the titles showed four of these articles to be relevant. (38-41). Further scrutiny of articles 
that had been cited by these four studies revealed one additional relevant study. (42)  
Since negative findings are rarely reported in the title of published articles, it was 
difficult to identify studies where anaemia was not associated with HAND.  By screening 
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the major published literature on the risk factors for HAND in the era of ART, one study 
was identified where no association between Hb and HAND was found. (43)  A summary 
of the findings of these six studies is shown in Table 1. 
 
Four North American studies and one study from Cameroon have shown an association 
between anaemia and HAND. (38-41)   In the most recent of these, Kallianpur et al. of 
the CHARTER study group reported that in a North American cohort, where 70% of the 
study population was receiving ART, mean corpuscular volume and mean corpuscular 
haemoglobin were positively associated with all forms of HAND.  Additionally, anaemia 
was an independent predictor for the later development of HAND (Global Deficit Score ≥ 
0.5 or meeting Frascati criteria) during a 72-month follow-up period. (41)  
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Table 1.  Studies of the  association between low haemoglobin and HAND 
 
Author, year 
published 
Country Study 
size  
Participants Study Design Clinical 
characteristics 
of study 
sample 
Definition 
and 
Prevalence of 
Anaemia 
 
Findings 
J McArthur et 
al. 1993 
North 
America 
492 Male; Mean 
age 37yrs 
Longitudinal 
cohort 
All had AIDS 
defining illness 
suggesting 
severe immune 
compromise 
Not reported,  
haemoglobin 
recorded as 
continuous 
variable 
On multivariate analysis an 
increase in haemoglobin (per 
additional 2g/dl) 1- 6 months 
prior to ART showed relative 
hazard (95% CI) of 0.6 (0.38-
0.96) for HAD* on follow up 
 
A Qureshi et al. 
1998 
North 
America 
19462 Predominantly 
male (85%); 
95% younger 
than 50yrs 
Longitudinal 
folder review 
45% CD4 
<200cells/μL; 
45% received 
zidovudine 
Anaemia 
defined as: 
women Hb 
<10g/dL & 
men Hb  
<11g/dL  
 
Prevalence 
27% 
 
Low haemoglobin showed 
relative risk (95%CI) of 2.8 
(2.4-3.2) for HAD** 
Tozzi et al. 
2005 
 
Italy 432 Predominantly 
male (71%); 
Mean age 
39yrs 
Survey Mean CD4 
count 301 
cells/µL; 76% 
receiving ART 
Not reported,  
haemoglobin 
recorded as 
continuous 
variable 
 
Haemoglobin showed no 
association with neurocognitive 
impairment as measured by a 
neuropsychological test battery 
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Njamnshi et al. 
2009 
Cameroon 185 Predominantly 
female (67%); 
Mean age 
37yrs 
Cross-
sectional 
analysis 
Mean CD4 
count 265 
cells/µL;  
Anaemia 
defined as: Hb 
<10g/dL 
 
Prevalence 
35% 
 
Anaemia showed odds 
ratio(95% CI) of 1.16 (1.00-
1.31) for IHDS*** ≤10 
M Marquine et 
al. 2014 
North 
America 
601 Predominantly 
male (88%); 
Mean age 
42yrs64 
Longitudinal 
cohort 
64% had AIDS 
defining 
illness; 63% 
received ART 
Anaemia 
defined as Hb 
<10g/dL 
 
Prevalence 2% 
 
Anaemia showed adjusted odds 
ratio (95%CI) of 2.24(1.01-
5.00) for global neurocognitive 
impairment****. 
 
A Kallianpur et 
al. 2015 
North 
America 
1261 Predominantly 
male (77%); 
Mean age 
43yrs 
Longitudinal 
cohort 
Median CD4 
nadir 181 
cells/μL; 70% 
receiving ART 
Anaemia 
defined as: 
women Hb 
<11.5g/dL  
& men Hb 
<13 g/dL 
 
Prevalence 
15% 
 
  
Baseline anaemia showed 
adjusted hazards ratio (95%CI) 
of 1.55(1.13–2.12) for 
HAND**** *during 72-month 
follow up 
*Clinical diagnosis, see McArthur et al. 1993, ** Centre for Disease Control’s 1987 clinical criteria for HAD,  
*** International HIV Dementia Scale, **** Neurocognitive impairment defined as: Global Deficit Score ≥ 0.5,  
***** HAND defined as: Global Deficit Score ≥ 0.5 or meeting Frascati criteria 
17 
 
It should be noted that an exact causal mechanism through which anaemia contributes to 
development of neurocognitive impairment has not been demonstrated however, the 
following mechanisms have been suggested. (44) 
Haemoglobin is an essential determinant of the oxygen delivery capacity of blood.  
Therefore, although not clinically proven, it is possible that anaemia can be viewed as a 
state of chronic cerebral hypoxia which may cause, or worsen, neurocognitive 
impairment. (45)  It has been shown that acute onset hypoxia causes cognitive 
impairment and that supplementary oxygen administration can improve cognition. (46, 
47)  In addition, other chronic conditions associated with suboptimal cerebral oxygen 
delivery such as obstructive sleep apnoea and chronic hypotension have a negative 
impact on neurocognitive performance. (48, 49)  Together, findings provide 
circumstantial support to the general hypothesis that anaemia, on the basis of low grade 
chronic hypoxia, can lead to neurocognitive impairment.    
Some of the specific aetiological mechanisms that give rise to anaemia can theoretically 
be linked with impaired cognition.  Examples include: a) reduced erythropoietin, b) iron 
deficiency, c) vitamin B12/folate deficiency, d) systemic inflammation associated with 
chronic disease and e) accelerated senescence associated with HIV.  
a) Erythropoietin is known for its function in regulating red blood cell production.  
Additionally, a growing body of evidence shows that erythropoietin is neuro-
protective. (50)  Erythropoietin protects the CNS against oxidative stress, can 
possibly reduce tau phosphorylation and protects against-β-amyloid-induced 
apoptosis. (51-53)  Anaemia is associated with low erythropoietin and therefore it is 
plausible that in the presence of anaemia erythropoietin related neuro-protection is 
reduced. (35)  
 
b) The presence of iron deficiency has been associated with impaired neurocognitive 
performance. (54)  As noted, haemoglobin is a cellular protein that regulates the 
oxygen carrying capacity of erythrocytes.  Iron is essential in the production of 
haemoglobin and therefore it is possible, in the context of low iron levels, that the 
blood’s oxygen carrying capacity will be reduced.  This may in turn lead to a degree 
of brain hypoxia.  Additionally, iron is an important micronutrient for normal cellular 
function and thus low iron levels can also be directly responsible for impaired 
neuronal function. (55)   
 
c) Vitamin B12 is another essential micronutrient important for erythrocyte and 
cognitive function.  Vitamin B12 deficiency is known to be associated with both 
Alzheimer’s dementia and vascular dementia. (56)  Characteristically, B12 deficiency 
is associated with the classical hematological feature of macrocytic anaemia.  As in 
the case of erythropoietin and iron deficiency, B12-related anaemia can be thought of 
18 
 
as both a causal factor as well as a proxy marker of an additional neuropathological 
process. 
 
d) The presence of anaemia in itself can also be considered as a marker of general ill-
health.  This is particularly relevant in the setting of HIV since HIV associated 
anaemia is strongly associated with more advanced immune compromise.  Anaemia 
may therefore serve as a proxy marker of immunosuppression in PLHIV, a well-
known risk association of HAND.  
 
e) Lastly, anaemia may be a marker of the accelerated senescence associated with HIV.  
Since this accelerated cellular aging process has also been suggested to be a risk 
factor for HAND, it is possible that anaemia and HAND can co-occur on the basis of 
a shared aetiological mechanism.   
The association between Hb/anaemia and HAND has not been assessed in a South 
African study population established on ART.  It is important to highlight some of the 
differences that exist between HIV infected populations in Sub-Saharan Africa and the 
study cohorts shown in Table 1.  
Firstly, certain demographic characteristics are unique to African cohorts.  The most 
notable of these is that, in Africa, a large proportion of the total HIV infected population 
is female.  In contrast, most study populations in North America consist of Caucasian 
males.  Clear differences exist between the normal Hb distributions for females as 
compared to males and these differences may impact on the relationship between Hb 
level and physiological performance.   
There are also socio-economic differences between African and North American 
populations.  The majority of the PLHIV in Sub-Saharan Africa face severe 
socioeconomic stressors and may be at higher risk of micronutrient deficiencies that can 
give rise to anaemia.  In addition, co-infection with opportunistic infections such as 
pulmonary tuberculosis and helminth infections, which can both cause anaemia, is 
common in PLHIV in Sub-Saharan Africa.  
Finally, differences exist with regards to the predominant clade of HIV-1.  In sub-
Saharan Africa the clade C subtype is responsible for the vast majority of HIV infections 
whereas in North America clade B accounts for most cases of infection.  It is possible 
that these two clades of HIV may have different virulence with regards to their 
haematological effects. 
To the best of our knowledge, it is currently uncertain whether anaemia harbors any 
clinically significant risk for neurocognitive impairment in South Africa.  We consider 
this as an important research question because if anaemia is indeed a risk factor for 
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HAND, then it will fall into the rare category of potentially modifiable risk factors.  This 
would have clear implications for clinical practice in South Africa. 
Our aim with this present study was to investigate the potential association between 
anaemia and HAND in a HIV infected South African study population where participants 
were clinically stable and on established ART.    
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2 Study hypothesis, aim and objectives 
2.1 Study Hypothesis 
Haemoglobin levels are associated with neurocognitive impairment in PLHIV in South 
Africa. 
2.2 Aim 
To determine the association between haemoglobin level and neurocognitive impairment 
in PLHIV who are virally suppressed and have received at least 6 months of ART. 
2.3 Objective  
To perform a cross-sectional analysis of an existing dataset (57) to explore whether 
haemoglobin, mean corpuscular volume (MCV) or mean corpuscular haemoglobin 
(MCH) is associated with neurocognitive function, as assessed by global deficit score 
(GDS).  
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3 Methodology 
3.1 Study Design 
We conducted a cross-sectional secondary data analysis of a randomised placebo 
controlled trial that evaluated the efficacy of lithium carbonate for the treatment of 
HAND. (57) 
3.2 Study Population 
The study population consisted of PLHIV who were established on ART for at least 6 
months. Study population details have been published. (57) 
 
3.3 Sample size 
 
One-hundred and forty-seven individuals were screened.  A secondary data analysis was 
done of the 129 individuals who had both neurocognitive screening and phlebotomy for 
FBC performed. (Figure 1)  An estimate of statistical power based on sample size 
suggested that our study was powered at 80% certainty.  
 
  
   
 
 
 
 
 
 
 
 
 
* Full Blood Count 
** Global Deficit Scale  
Figure 1: Summary showing how participants were included in this study 
3.4.1 Inclusion criteria  
 
Study participants had to have had neurocognitive screening and full blood counts done.  
For consent purposes, they had to be older than 18 years and cognitively well enough to 
provide informed consent.  To minimize confounders, they had to be otherwise clinically 
well with systemic viral suppression (HIV PCR <400 copies/mL). 
 
3.5  Exclusion criteria 
 
All individuals screened at 
enrollment (n=147) 
Participants eligible for inclusion 
in this study (n=129) 
Excluded (n=18)  
 no FBC* (n=13) 
 no GDS** (n=5)  
22 
 
Exclusion criteria have been published. (57)  Of note, participants were excluded if 
neuropsychiatric disorders, serious psychiatric symptoms or imaging structural 
abnormalities were present.  
 
3.6  Participant recruitment  
 
Participants were actively recruited in the waiting rooms of two HIV treatment clinics in 
Cape Town. (57) 
 
3.7  Withdrawal of participants  
 
Participants were free to withdraw from the study at any stage. (57) 
 
3.8  Participants’ obligations 
  
Participants had to notify the investigator if they were unable to follow any study 
procedures, experienced any adverse events, ingested any new drugs or received 
instructions from a health care provided to change any chronic medication dosages. (57) 
 
3.9  Study procedure   
 
As published. (57)  
For the purpose of this study it was important to note that the following blood 
investigations were done: 
 Full blood count including differential count and red cell indices 
 Chemistry: thyroid stimulating hormone (TSH) (T3 and T4 was be performed if 
TSH was abnormal), sodium, potassium, calcium, urea and creatinine  
 Plasma viral load  
 CD4+ count  
 Rapid plasma reagin test (RPR)  
 Vitamin B12 
 
3.10 Haematological analyses and definition of anaemia 
 
3.10.1 Haematological analyses  
 
Phlebotomy for full blood counts was only done at study entry.  All blood samples were 
collected in appropriate ethylenediaminetetraacetic acid (EDTA) tubes.  An accredited 
South African pathology laboratory service provider was used for the processing of these 
samples.  The automated processing of haematological samples was done by Advia 
machines.  All results were signed out by qualified haematological pathologists. 
3.10.2 Definition of anaemia 
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A stringent definition of anaemia, as reflected by a serum haemoglobin level of < 10 
g/dL, was used.  This definition was in keeping with the definition used by most South 
African studies investigating anaemia in HIV positive populations and was also in 
keeping with the WHO toxicity grading systems definition of anaemia. (33) 
 
3.11  Determination of GDS 
 
The GDS has been validated for use in HIV and summarises the neuropsychological test 
results of selected cognitive domains and adjusts for age, education, gender and ethnicity 
(Carey, 2004).  Neurocognitive impairment was defined as a GDS score of greater than 
0.5.  In our statistical analysis we looked at associations with GDS as a continuous 
variable.  In addition, we explored group differences between participants with normal or 
abnormal GDS scores.  
3.12 Neuropsychological test battery 
 
The neuropsychological test battery was performed by trained technicians.  This battery 
was designed to be sensitive to the neurological functions affected by HIV. The standard 
battery includes the following:  
 Attention: the Mental Alternation Test (MAT) and the Mental Control Test 
(MCT);  
 Learning and memory: the Hopkins Verbal Learning Test (HVLT) and the 
Brief Visuospatial Memory Test (BVMT);  
 Motor speed: Finger Tapping (FT) and the Grooved Pegboard Test (GP);  
 Psychomotor speed: Trail Making Test part A (TMTA), Colour Trails Test 
1(CT1) and Digit Symbol-Coding (DSC);  
 Executive function: Colour Trails Test 2 (CT2), Stroop Colour-Word test 
(SCW), Wisconsin Card-Sorting Test (WCST);  
 Language: category fluency;   
 Depression score: Center for Epidemiologic Studies Depression scale (CES-
D)  
  
3.13 Data management  
 
The dataset used for this research did not contain the subject’s personal identities.  Steps 
involved in data management, including those relating to the development and 
management of the database were performed in accordance with standard operating 
procedures that were consistent with regulatory requirements.  The data set for this 
secondary analysis was password protected.  The data will be stored for 5 years following 
submission of this MMed. 
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3.14 Statistical Plan 
  
In keeping with the aims of our study, the following analysis was conducted: 
A descriptive analysis of the risk associations for HAND in participants who were 
screened for entry into the Li in HAND RCT study.   
Univariate analysis was performed to assess the association between GDS and variables 
of interest including age, level of education, CD4 count, Red cell count, Hb, MCV, 
MCH, TSH and Vit B12.  T-tests and Chi-square tests where used as applicable.  An 
attempt was made to log transform all nonparametric data in order to use parametric 
statistical tools.  Where such transformations were not possible nonparametric statistical 
tools were used- namely Mann-Whitney and Fisher Exact tests.  Statistical significance 
was set at the .05 level.   
All variables that reached significance on univariate analysis were included in a series of 
regression analyses, using GDS as the dependent variable.  
In addition to this, the data was binarized on the basis of GDS using 0.5 as cutoff. 
Descriptive and cross-sectional analysis was performed by J Vermaak using STATA/IC 
11.  A final data analysis was supervised by a UCT based statistician, Michelle Henry. 
3.15  Ethical considerations 
3.15.1 Informed consent 
As published. (57) 
 
3.15.2 General ethical principles 
 
The protocol for this sub-study was presented and approved in a peer-reviewed manner.  
Ethical approval was obtained from the University of Cape Town’s Human Research 
Ethics Committee, HREC 530/2017. 
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Background 
Sub-Saharan Africa, the epicenter of the global population of people living with HIV (PLHIV), 
is estimated to have more than 25 million PLHIV.  In the era before the widespread availability 
of antiretroviral therapy (ART), anaemia (low serum haemoglobin) was a common clinical 
finding that was seen as a potential risk factor for HIV-associated neurocognitive impairment. 
The association between haemoglobin levels and neurocognitive function has not been assessed 
in a Sub-Saharan study population in the era of ART.    
Methods 
A cross-sectional secondary data analysis was performed to assess the association between serum 
haemoglobin level and neurocognitive function. One hundred and twenty-nine participants who 
had both neurocognitive test (global deficit score) and full blood count results performed as part 
of a randomised placebo controlled trial were included. 
Results 
The majority of our participants were female (87%) with a mean age of 37 ±7.78 years.  
Participants were all established on ART with a median CD4 count of 495 cells/ µL (IQR=315-
629).  The median haemoglobin level was 12.2 (IQR=11.6-13.00) and anaemia was present in 
8.5%.  Serum haemoglobin level was not associated with global deficit scores (GDS) and fewer 
years of education was the only independent risk association for GDS-defined neurocognitive 
impairment.   
Conclusion 
We found that in South Africans, who are established on ART, anaemia is less common than in 
the pre-ART era and importantly, that low-normal serum Hb levels do not present a risk for 
GDS-defined neurocognitive impairment.  These findings are relevant as they show that 
aggressive management of low-normal Hb levels is not necessary if individuals are otherwise 
clinically well and virally suppressed. 
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Introduction  
Sub-Saharan Africa, the epicenter of the global population of PLHIV, is estimated to have more 
than 25 million PLHIV.  In the last two decades major strides have been made with regards to 
improved access and the early initiation of ART.  This has impacted on both the epidemiology 
and presentation of clinical syndromes associated with HIV.  Pre-ART typical complications of 
HIV were related to severe immune compromise.  However, in the modern era of ART, HIV is 
now more frequently associated with conditions related to chronic low-grade immune 
dysregulation, accelerated cellular aging and the negative effects of long term ART use. (1)  
This change in the clinical picture of HIV is particularly evident with regards to the 
neurocognitive disorders associated with HIV.  In the pre-ART era advanced HIV infection was 
often complicated by a progressive subcortical dementia with psychomotor slowing and severe 
cognitive impairment, a condition then called HIV-dementia (HAD). (2)  With the advent of 
ART, the incidence of HIV-dementia has been reduced.  However, it is now evident that milder 
forms of neurocognitive impairment are common amongst PLHIV. (3)  In fact, it has been 
estimated that 50% of PLHIV, who are clinically stable and receiving ART, may be found to 
have neurocognitive impairment on objective neuropsychological testing. (4)  The awareness of 
this spectrum of neurocognitive impairment in PLHIV has seen an expansion of the nosology 
used for the HIV associated neurocognitive disorders (HAND). (5)  HAND now serves as an 
umbrella term which can be further defined on the basis of both the degree of functional 
impairment and the associated objective neuropsychological test findings.  As the term suggests, 
the individual with asymptomatic neurocognitive impairment (ANI) does not subjectively 
experience any impairment in everyday functioning but neuropsychological testing demonstrates 
a performance of at least 1.0 standard deviation (SD) below the mean for age-education-
appropriate norms.  In mild neurocognitive disorder (MND) the individual has some degree of 
interference with day-to-day cognitive functioning and neuropsychological testing demonstrates 
a performance of at least 1.0 SD below the mean for age-education-appropriate norms.  HIV- 
associated dementia (HAD) represents the severest form of impairment and the patient typically 
has marked interference with daily functioning with neuropsychological testing demonstrating a 
performance of greater than 2.0 SD below demographically corrected means. (5) 
Epidemiological data shows that amongst PLHIV who are receiving ART approximately: 30% 
have ANI, 20% have MND and 2%-8% have HAD. (6)  The overall figure of HAND is expected 
to rise even further as the global HIV positive population ages. (6)  This is of serious concern 
because HAND is associated with significant morbidity and has been shown to have a negative 
impact on everyday function, employability and ART adherence. (7, 8, 9)  Of further concern is 
the lack of a definitive adjuvant treatment for the management of HAND in PLHIV who are 
clinically stable on ART. (6, 10) 
 
Anaemia and HAND 
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Anaemia is the most common hematological abnormality in PLHIV and in the pre-ART era 
prevalence rates as high as 90% were reported. (11)  As with HAND the introduction of ART 
markedly reduced the incidence and prevalence of anaemia to between 5% and 10% in PLHIV 
who are established on ART. (12, 13, 14)   
 
The aetiological mechanisms underlying anaemia in HIV are vast.  The most common form of 
anaemia in HIV is a normochromic normocytic anaemia with a low reticulocyte count, normal 
iron stores and impaired erythropoietin response.  This pattern of anaemia is typical of chronic 
inflammation and it is therefore thought that the immune dysregulation associated with HIV is 
the major pathophysiological mechanisms underlying most HIV associated anaemia. (15)  Apart 
from the above, HIV may have a direct suppressive effect on the cytokine cascade responsible 
for normal erythropoiesis.  Actively replicating HIV appears to suppress the body’s normal 
physiologic response to anaemia. (16)  Auto-antibodies against erythropoietin, the hormone that 
stimulates erythropoiesis, have also been demonstrated in HIV. (17)  The common opportunistic 
infections and the malignancies that affect PLHIV can also contribute to anaemia. (15) 
Nutritional deficiencies, also more common in PLHIV, often result in anaemia.  Namely, iron 
deficiency, associated with microcytic anaemia, and vitamin B12/folate deficiency which is 
typically associated with macrocytic anaemia.  Lastly drugs used in HIV can in themselves result 
in anaemia including antiretroviral drugs, prophylactics for opportunistic infections and the drugs 
used in the treatment of opportunistic infections. (15) 
In the pre-ART era, a risk association was shown between anaemia and HAD. (18-21)  More 
recently, Kallianpur et al. of the CHARTER study group reported that in a North American 
cohort, where 70% of the study population was receiving ART, mean corpuscular volume and 
mean corpuscular haemoglobin were positively associated with all forms of HAND. 
Additionally, anaemia was an independent predictor for the later development of HAND (Global 
Deficit Score ≥ 0.5 or meeting Frascati criteria) during a 72-month follow-up period. (21)  
The exact mechanism through which anaemia can contribute to the development of 
neurocognitive impairment has not been demonstrated but the following mechanisms have all 
been suggested  
As the essential determinant of the oxygen delivery capacity of blood, it is possible that anaemia 
might represent a state of chronic low-grade cerebral hypoxia. (22, 23)  This hypothesis has not 
been tested in vivo and it is uncertain at which Hb level the hemodynamic system’s ability to 
optimally oxygenate the brain is compromised. However, it has been shown that acute onset 
hypoxia causes cognitive impairment and that supplementary oxygen administration can improve 
cognition. (24, 25)  In addition, other chronic conditions associated with suboptimal cerebral 
oxygen delivery such as obstructive sleep apnoea and chronic hypotension have a negative 
impact on neurocognitive performance. (26, 27)  
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Apart from the anaemia itself, some of the aetiological mechanisms that give rise to anaemia can 
theoretically be linked with neurocognitive function.  Examples include: systemic inflammation 
associated with chronic disease, reduced erythropoietin, iron deficiency, vitamin B12 deficiency, 
and accelerated senescence associated with HIV.  HIV associated anaemia is strongly associated 
with more advanced immune compromise.  To this extent anaemia may serve as a proxy marker 
of immunosuppression in PLHIV.  Advanced immunosuppression is a well-known risk 
association of HAND.   
Erythropoietin is known for its function in regulating red blood cell production.  There is also a 
growing body of evidence showing that erythropoietin is neuro-protective. (28) Erythropoietin 
protects the CNS against oxidative stress, can possibly reduce tau phosphorylation and protects 
against-β-amyloid-induced apoptosis. (29, 30, 31)  Anaemia is associated with low 
erythropoietin and therefore it is plausible that in the presence of anaemia erythropoietin related 
neuro-protection is reduced. (15)   
Iron deficiency has also been associated with impaired neurocognitive performance. (32)  Iron is 
an important micronutrient for normal cellular function and therefore low iron levels can also be 
directly responsible for impaired neuronal function. (33)  Additionally, iron is also important for 
its role in the production of haemoglobin and therefore iron deficiency anaemia may be 
associated with HAND on the basis of anaemia being a proxy marker of systemic iron 
deficiency.  
Vitamin B12 is another essential micronutrient important for erythrocyte and cognitive function.  
Vitamin B12 deficiency is known to be associated with both Alzheimer’s dementia and vascular 
dementia. (34)  Characteristically though, B12 deficiency is also associated with macrocytic 
anaemia.  As in the case of erythropoietin and iron deficiency, B12-related anaemia can be 
thought of as both a causal factor as well as a proxy marker of an additional neuropathological 
process. 
Lastly, anaemia may be a marker of the accelerated senescence associated with HIV.  Since this 
accelerated cellular aging process has also been identified as a risk association for HAND, it is 
possible that anaemia and HAND can co-occur on the basis of a shared aetiological mechanism. 
(15)   
The association between anaemia and HAND has not been explored in a South African study 
population in the era of ART. We consider this as an important research question because if 
anaemia is indeed a risk factor for HAND, even in the setting of established ART, then it may 
represent a potentially modifiable risk that can be prevented or treated.  This it would have clear 
implications for the clinical management of HAND in South Africa. 
This study aimed to investigate the potential association between anaemia and HAND in a HIV 
infected South African study population where participants were clinically stable and on 
established ART.    
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Methods  
Study design  
A cross-sectional secondary data analysis was performed to assess the association between serum 
haemoglobin level and neurocognitive function. One hundred and twenty-nine participants who 
had both neurocognitive test (global deficit score) and full blood count results performed as part 
of a randomised placebo controlled trial were included. (35) 
Criteria for eligibility 
For consent purposes, participants had to be older than 18 years and cognitively well enough to 
provide informed consent. All participants were receiving ART and they were otherwise 
clinically well with systemic viral suppression (HIV PCR <400 copies/mL).  Participants were 
excluded if neuropsychiatric disorders, serious psychiatric symptoms or imaging structural 
abnormalities were present. 
Study procedure   
This has been previously published. (35) Phlebotomy for full blood counts was done at study 
entry.  All blood samples were collected in appropriate EDTA tubes.  An accredited South 
African pathology laboratory service provider was used. The automated processing of 
haematological samples was done by Advia machines.  All results were signed out by qualified 
haematological pathologists.  A stringent definition of anaemia, as reflected by a serum 
haemoglobin level of < 10 g/dL, was used.  This definition was in keeping with the definition 
used by most South African studies investigating anaemia in HIV positive populations and was 
also in keeping with the WHO toxicity grading systems definition of anaemia. (36) The Global 
Deficit Score (GDS) has been validated for use in HIV and summarizes the neuropsychological 
test results of selected cognitive domains and adjusts for age, education, gender and ethnicity 
(43).  Neurocognitive impairment was defined as a GDS score of greater than 0.5.  
Statistical Analysis 
An initial descriptive analysis was performed. Univariate analysis was then used to assess the 
association between GDS and variables of interest. T-tests and Chi-square tests where used as 
applicable.  An attempt was made to log transform all nonparametric data in order to use 
parametric statistical tools.  Where such transformations were not possible nonparametric 
statistical tools were used- namely Mann-Whitney and Fisher Exact tests.  Statistical significance 
was set at the .05 level.  Following the univariate analyses a regression analyses was performed, 
using GDS as the dependent variable. Thereafter the data was binarized on the basis of GDS 
using 0.05 as cutoff.  Descriptive and cross-sectional analysis was performed by J Vermaak 
using STATA/IC 11.  A final data analysis including the regression analyses was supervised by a 
UCT based statistician, Michelle Henry. 
 
Results 
Study population characteristics 
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A total of 129 study participants were included in the analysis.  The majority were female (87%) 
and the mean age was 37 years (SD=7.78). (Table 4.1) The mean number of years of education 
was 9.44 years (SD=1.77).  Participants were all established on ART and CD4 counts were 
generally well-preserved with a median of 495 cells/ µL (IQR=315-629).  
Haemoglobin and the distribution of haemoglobin 
Overall the median haemoglobin was 12.2g/dL. (Table 4.1)  Haemoglobin was not normally 
distributed and there was a narrow interquartile range of 11.6 to 13.0g/dL - mostly low normal. 
(Figure 4.1)  Anaemia was present in 8.5% of the study population.  The mean values for Mean 
corpuscular volume, 97.56 fL and Mean corpuscular haemoglobin, 31.23 pg were both within 
normal range. 
Normal GDS versus impaired GDS 
When assessing group differences between patients who had a normal GDS vs. those with GDS- 
defined neurocognitive impairment only age (p=.003) and years of education (p=.002) showed 
statistical significance on univariate analysis. (Table 4.2)  Haemoglobin, red cell indices and 
Vitamin B 12 did not show association with GDS. (Figure 4.2) 
A stepwise hierarchical regression found that only education significantly predicted GDS score 
(R = .423, R² = .179, F [1,116] = 25.29, p < .001) and explained 18% of the variance.  
Participants with a higher education level had lower GDS scores, indicating better cognitive 
functioning. (Table 4.3)   
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Table 4.1 Study population characteristics (n = 129) 
 
  
Mean age (SD) 37 (7.78) 
Gender:  
     Female (%) 112 (87) 
     Male (%) 17 (13) 
Years of education (SD)  9.44 (1.77) 
CD4 count, median (IQR) 495 (315-629) 
Haemoglobin, median (IQR) 12.2 (11.6-13.00) 
      Anaemia (%) 11 (8.53) 
Mean corpuscular volume, mean (range) 97.56 (62-125) 
Mean corpuscular haemoglobin, mean (range) 31.23 (16-39) 
Red Cell Count, mean (range) 3.93 (2.63-4.96) 
Platelet count, mean (range) 281.11 (140-549) 
Thyroid stimulating hormone, mean (range) 2.20 (0.27-18.17) 
Vit B12, mean (range) 256.91 (89-523) 
Global deficit score, mean (range) 1.04 (0-3.53) 
     GDS impaired (%) 96 (75) 
SD = standard deviation, IQR = inter quartile range 
 
Figure 4.1 Distribution of Haemoglobin   
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38 
 
Table 4.2 Comparison between participants with normal GSD vs. those with impaired GDS 
 
 Normal GDS 
(<0.5) 
(N=32) 
Impaired GDS 
(≥0.5) 
(N=97) 
p 
Age, mean (range) 34 (24-53) 39 (23-60) .003 
Gender:    
     Female (%) 28 (88) 84 (87) * 
     Male (%) 4 (13) 13 (13)  
Years of education (SD)  10.35 (1.80) 9.15 (1.66) .002 
CD4 count, median (IQR) 470 (318-626) 485 (299-633) .94 
    
Haemoglobin, median (IQR) 12.5 (11.6-13.3) 12.1 (11.6-12.9) .31 
      Anaemia (%) 2 (6) 9 (9) ** 
Mean corpuscular volume, mean (range) 97.38 (79-124) 97.62 (62-125) .60 
Mean corpuscular haemoglobin, mean (range) 31.56 (25-39) 31.12 (16-39) .74 
Red Cell Count, mean (range) 3.97 (3.12-4.96) 3.91 (2.63-4.93) .53 
Platelet count, mean (range) 273.81 (166-410) 283.52 (140-549) .50 
Thyroid stimulating hormone, mean (range) 2.71 (0.74-18.17) 2.04 (0.27-7.78) .81 
Vit B12, mean (range) 250.72 (119-466) 259 (89-523) .93 
Continuous variables shown as median (inter quartile range) * No significance difference for male and 
female distribution (M = 0.89±0.54 vs M = 1.04±0.67; t(126) = -0.85, p = .397) 
** No significance between participants with or without GDS defined neurocognitive impairment (Odds 
Ratio[95% Confidence Interval] = 0.65[0.13-3.19]) 
 
 
Figure 4.2 Scatterplot of Haemoglobin and GDS 
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Table 4.3 Correlation matrix between GDS and variables of interest  
 
  
GDS 
 
Education 
 
Age 
 
CD4 
 
RCC 
 
Hb 
 
MCV 
 
MCH 
 
Platelets 
 
TSH 
 
B12 
GDS 1.000 -.423** .264** -.013 -.081 -.131 .037 -.066 .135 .094 -.090 
Years of 
Education 
 1.000 -.308** .221* .047 .030 -.092 .010 -.113 -.172* .128 
Age   1.000 -.104 -.085 .001 .105 .089 .009 .086 -.066 
CD4 count    1.000 .012 .031 .021 .071 .048 .001 .072 
RCC     1.000 .669** -.532** -.349** -.004 .027 .095 
 H
b 
      1.000 .202* .446** -.147 .036 -.059 
MCV       1.000 .902** -.111 .071 -.148 
MCH        1.000 -.169* .031 -.139 
Platelets         1.000 -.048 .134 
TSH          1.000 .002 
B12           1.000 
Note. *p< .05. **p<.001. 
 
 
Discussion 
This cross-sectional study is the first African study to investigate the possible association 
between low serum haemoglobin (Hb) and HAND in an ART experienced and virologically 
suppressed population.  Anaemia was present in 8.5% of our participants and serum 
haemoglobin level was not associated with GDS-defined neurocognitive impairment. Fewer 
years of education was the only independent risk association for GDS-defined neurocognitive 
impairment.   
 
These findings are important because anaemia was a common finding in the pre-ART era with 
reported prevalence rates as high as 90%. Additionally, low haemoglobin represented a potential 
risk factor for neurocognitive impairment.  Our study shows that amongst individuals who are 
established on ART, anaemia is now less common than in the pre-ART era and importantly, that 
low-normal serum Hb levels do not present a risk for GDS-defined neurocognitive impairment.  
Our results are particularly relevant as our South Africa study population is representative of the 
larger Sub-Saharan population of PLHIV, the global epicenter of HIV.      
The 8.5% prevalence of anaemia that we identified was in keeping with the previously reported 
prevalence rates of 5.4% and 7.2% reported for two North American HIV positive female 
cohorts receiving ART. (13, 14)  The fact that the frequencies of anaemia is similar in African 
and North American cohorts receiving ART suggests that good viral control is probably the most 
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important protective factor against HIV associated anaemia. This is in keeping with the known 
pathophysiology of HIV associated anaemia, where immune dysregulation is the main 
contributor to reduced Hb levels. In addition to this, our finding also suggests that the other 
common aetiologies for anaemia such as iron deficiency, Vit B12 deficiency and opportunistic 
infections are unlikely to be major contributors to anaemia in the context of established ART.       
Our finding that low-normal serum Hb was not associated with GDS suggests that aggressive 
treatment of asymptomatic low-normal Hb levels is not indicated in otherwise well PLHIV. It 
further suggests that the potential physiological factors associated with low Hb, such as lower 
levels of erythropoietin, do not have a clinical effect on neurocognitive performance provided 
that Hb is in the low-normal range. 
As noted during the pre-ART era, select studies showed association between anaemia and 
HAND.  Our ART established study population showed significant differences to these studies 
with regard to both population and methodology.  Firstly, because all our participants where 
established on ART, our participants had a much higher mean CD4 count than the participants in 
the pre-ART era.  This is relevant because advanced immune compromise is a well recognised 
risk factor for both HAND and low Hb. (37, 15)  Therefore, in the pre-ART studies the 
association between anaemia and HAND might have been due to confounding.  Furthermore, we 
explored the association between Hb and GDS whereas most of the pre-ART studies examined 
the association between anaemia and severe neurocognitive impairment (HAD).  It is also 
notable that our participants were predominantly women compared to the pre-ART study 
populations who were mostly male.  This is of potential relevance because of the well-
established differences in the normal Hb distribution of men and women, with women generally 
having a lower Hb.  This difference in Hb distribution has led some to suggest that women, when 
compared to men, are physiologically superior with regards to functioning at low or low-normal 
Hb levels. (38)  It is therefore possible that our participants were potentially physiologically less 
affected by their low-normal Hb levels because they were female.  Lastly our study was done in 
Sub-Saharan Africa and therefore participants were most likely infected by HIV-1 clade C. 
Contrastingly, most of the pre-ART studies where done in North America where clade B 
predominates.  Different clades of the HIV virus exhibit different degrees of neurotoxicity with 
clade C (Sub-Saharan Africa and Southern Asia) being less neurotoxic than clade B. (39)  More 
recent in vitro research has shown that there are  differences in the HIV-1 Tat protein and 
specifically the dicysteine motif in Tat that is responsible for clade related differences in 
neurotoxicity. (40)  To the best of our knowledge the clade related effects on Hb and the risk for 
anaemia have not been explored.  
In our study, fewer years of education was the only factor which was independently associated 
with poorer GDS scores.  This finding was not unexpected as education level has a known effect 
on neuropsychological test performance. (41)  Higher levels of education may also increase 
neurocognitive reserve and as such, convey a degree of protection against neurocognitive 
impairment. (42)  
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Limitations to our study include: patient selection and limited data for the aetiology of low Hb 
levels.  We used data from an established research project where individuals who thought they 
may have some degree of neurocognitive impairment were invited to formal GDS screening.  
(35)  This may have resulted in a greater proportion of our participants having abnormal GDS 
scores.  However, because we primarily assessed association with GDS as a continuous variable, 
we believe that our exploratory analysis was sufficient to test our study hypothesis.  Secondly, 
although our study examined Hb level, red cell indices and Vitamin B12, the Li in HAND study 
did not measure iron or folate levels. This limited the conclusions that we could draw with 
regards to the aetiology of anaemia in our study.  
Our cross-sectional research focused on the association between Hb and neurocognitive function 
in the context of established ART.  We suggest that future research explores the effects of ART 
initiation on Hb levels and the longitudinal association between Hb level and neurocognitive 
outcomes. It would be of particular interest to investigate whether symptomatically low levels of 
Hb are associated with the later development of neurocognitive symptoms.  
Conclusion 
Our study shows that in South Africans who are well established on ART, anaemia is now less 
common than in the pre-ART era and importantly that low-normal serum Hb levels do not 
present a risk for GDS-defined neurocognitive impairment. These findings are relevant as they 
show that aggressive management of low-normal Hb levels is not necessary if individuals are 
otherwise clinically well and virally suppressed.     
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